R
Robby M. Weimer
Researcher at Genentech
Publications - 78
Citations - 6553
Robby M. Weimer is an academic researcher from Genentech. The author has contributed to research in topics: Synaptic vesicle & Caenorhabditis elegans. The author has an hindex of 40, co-authored 75 publications receiving 5610 citations. Previous affiliations of Robby M. Weimer include Howard Hughes Medical Institute & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes
Marcin Kowanetz,Xiumin Wu,John G. Lee,Martha Tan,Thijs J. Hagenbeek,Xueping Qu,Lanlan Yu,Jed Ross,Nina Korsisaari,Tim C. Cao,Hani Bou-Reslan,Dara Y. Kallop,Robby M. Weimer,Mary J. C. Ludlam,Joshua S. Kaminker,Zora Modrusan,Nicholas van Bruggen,Franklin Peale,Richard A.D. Carano,Y. Gloria Meng,Napoleone Ferrara +20 more
TL;DR: This study shows that metastatic tumors examined overexpress granulocyte-colony stimulating factor (G-CSF), which expands and mobilizes Ly6G+Ly6C+ granulocytes and facilitates their subsequent homing at distant organs even before the arrival of tumor cells.
Journal ArticleDOI
An open form of syntaxin bypasses the requirement for UNC-13 in vesicle priming
TL;DR: It is demonstrated that the open form of syntaxin can bypass the requirement for UNC-13 in synaptic vesicle priming, which is likely thatUNC-13 primesaptic vesicles for fusion by promoting the open configuration ofntaxin.
Journal ArticleDOI
Rapid redistribution of synaptic PSD-95 in the neocortex in vivo.
TL;DR: The data suggest that individual PSDs compete for PSD-95 and that the kinetic interactions between PSD molecules and PSDs are tuned to regulate PSD size.
Journal ArticleDOI
A post-docking role for active zone protein Rim.
Sandhya P. Koushika,Janet E. Richmond,Gayla Hadwiger,Robby M. Weimer,Erik M. Jorgensen,Michael L. Nonet +5 more
TL;DR: It is demonstrated that C. elegans unc-10 mutants lacking Rim are viable, but exhibit behavioral and physiological defects that are more severe than those of Rab3 mutants.
Journal ArticleDOI
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson,Maria Pihlgren,Nicolas Toni,Yvan Varisco,Anna Lucia Buccarello,Katia Antoniello,Sophie Lohmann,Kasia Piorkowska,Valerie Gafner,Jasvinder Atwal,Janice A. Maloney,Mark Z. Chen,Alvin Gogineni,Robby M. Weimer,Deborah L. Mortensen,Michel Friesenhahn,Carole Ho,Robert Paul,Andrea Pfeifer,Andreas Muhs,Ryan J. Watts +20 more
TL;DR: It is proposed that a humanized IgG4 anti-Aβ antibody that takes advantage of a unique Aβ binding profile, while also possessing reduced effector function, may provide a safer therapeutic alternative for passive immunotherapy for AD.